glp 1 oral drug Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients Structure Therapeutics Oral GLP-1 Obesity

Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer's and Parkinson's disease therapeutics

Meet our doctors Last reviewed: 19 Jun 2026 Sources Mounjaro KwikPen 10mg solution for injection in pre-filled pen SmPC, emc [accessed 25 May 2026] Once-Weekly Semaglutide in Adults with Overweight or Obesity, The New England Journal of Medicine (NEJM) [accessed 25 May 2026] Ozempic SmPC, emc [accessed 25 May 2026] Rybelsus 3 mg, emc [accessed 25 May 2026] Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes, NEJM [accessed 25 May 2026]

But for many, the excitement of seeing the number on the scale go down has been tempered by an unexpected surprise: increased hair shedding

Apart from this, newer versions of the guidelines that recommend the use of these drugs in certain patient populations have added to their market position

Funch D., Mortimer K., Li L., et al., Is There an Association Between Liraglutide Use and Female Breast Cancer in a RealWorld Setting?, Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 11 (2018): 791806